Sign up
Pharma Capital

Holista CollTech secures distribution rights for unique algae supplement

The stem-cell growth promoting algae is harvested from Klamath Lake in Oregon.
an old couple
The supplement has anti-aging properties

Holista CollTech Limited (ASX:HCT) has secured the global distribution rights for a supplement, sourced from algae found in pristine conditions in a lake in the U.S., that can enhance stem cell growth.

The Aphanizomenon Flos-aquae (AFA) algae is harvested from Klamath Lake in Oregon, which is considered to be the most pristine environment in North America after Alaska.

When consumed, the Klamax™ algae supplement is believed to enhance general wellness and anti-aging health, by promoting and supporting a normal neurological, somatic and stem-cells physiology.

The algae’s unusual properties are due in part to the fact that it grows on the surface of the lake that sits on top of a 7,700-year bed of rich volcanic ash.

Developed by scientist Dr Stefano Scoglio, the product has a high concentration of a molecule endowed with neuromodulating, immune-enhancing and neuronal stem-cell promoting activities.

Holista intends to develop oral and transdermal preparations to be sold through network marketing platform, iGalen International Inc.

In September 2017, Holista announced that it was acquiring a 47% stake in iGalen from Dr Rajen Manicka for a nominal consideration of US$1 pending shareholder approval.

iGalen has more than 12,500 distributors worldwide, and intends to enter Australia and New Zealand, in addition to the U.S., Canada, Malaysia, Singapore and Philippines.

In August 2017, Holista had secured the global rights for Emulin®, an all-natural carbohydrates manager developed by two Nobel Prize nominees.



Register here to be notified of future HCT Company articles
View full HCT profile

Holista Colltech Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.